HOTH
Hoth Therapeutics Inc

11,529
Mkt Cap
$16.13M
Volume
354,297.00
52W High
$2.12
52W Low
$0.6554
PE Ratio
-0.98
HOTH Fundamentals
Price
$1.04
Prev Close
$1.08
Open
$1.06
50D MA
$1.13
Beta
1.00
Avg. Volume
135,107.45
EPS (Annual)
-$1.28
P/B
1.91
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation Hoth Therapeutics Reaches Key EU Regulatory Inflection Point...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
Hoth Therapeutics Files Two Provisional Patents To Build Oncology Dermatology Platform
(RTTNews) - Hoth Therapeutics (HOTH) has filed two U.S. provisional patent applications that expand its intellectual property portfolio and lay the foundation for a new oncology-focused dermatology...
Nasdaq News: Markets·18d ago
News Placeholder
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings...
PR Newswire·18d ago
News Placeholder
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging...
PR Newswire·2mo ago
News Placeholder
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and...
PR Newswire·2mo ago
News Placeholder
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy...
PR Newswire·3mo ago
News Placeholder
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical...
PR Newswire·3mo ago
News Placeholder
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited
The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.
Stocktwits·1y ago
<
...
1
>

Latest HOTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.